HALO: Multiplikator P/S Halozyme Inc.

Tandha merek Halozyme Corp (HALO)

The price/sales multiple for Halozyme Therapeutics (HALO) reflects the valuation dynamics of Halozyme Therapeutics (HALO), where 6.30 represents the current metric. The business model relies on outsourcing enzyme production to third-party contractors. Revenues are diversified through the sale of drug delivery rights to global players. The high margins of the ENHANZE platform ensure a steady capital inflow, confirming the relevance of its technological solutions.

Halozyme Inc. - Rasio rega marang pendapatan HALO (periode 04.07.2022 - 16.11.2026)

Halozyme Therapeutics, Inc. (HALO) - rincian metrik lan laporan keuangan

- rega saham lan konsensus proyeksi valuasi:
Analisis fundamental perusahaan:HALO (Halozyme)
Barang unggulan Halozyme

The P/S multiple compares market capitalization to annual sales volume, allowing for an assessment of the premium paid per unit of revenue regardless of profit. By analyzing the ratio of company value to annual revenue, an investor determines whether the growth premium is justified, which is critical for Halozyme Therapeutics (HALO) when scaling licensing royalties and monetizing enzyme technologies with minimal operating expenses.

Perusahaan pesaing

ONC - Rega marang dodolan|Multiplikator P/S RVMD (revmed.com)|Koefisien rega marang pendapatan Ascentage (AAPG)|CGON: Kapitalisasi marang pendapatan|Rega marang dodolan UroGen Pharma Ltd.|BCAX: Multiplikator P/S|PSNL - Koefisien rega marang pendapatan|ERAS (Erasca Oncology) - Multiplikator P/S|Multiplikator P/S Delcath Systems, Inc.|Rasio rega marang pendapatan ymabs.com (YMAB)|Rasio rega marang pendapatan AURA (Aura Biosciences, Inc.)|Candel Therapeutics - Kapitalisasi marang pendapatan|Accuray Inc. (ARAY) - Rega marang dodolan|SELLAS Life Sciences Group, Inc. - Multiplikator P/S|Rasio kapitalisasi pasar marang pendapatan ACTU (Actuate Therapeutics, Inc.)|Citius Oncology (CTOR) - Rasio rega marang pendapatan|HURA - Koefisien rega marang pendapatan|TARA (Protara Therapeutics, Inc.) - Multiplikator P/S|Multiplikator P/S Fate Therapeutics Inc|Multiplikator P/S WHWK|Multiplikator P/S TScan Therapeutics Inc (TCRX)|Rasio rega marang pendapatan championsoncology.com CSBR|XBIT - Kapitalisasi marang pendapatan|CVM - Rasio rega marang pendapatan|Rasio kapitalisasi pasar marang pendapatan OSTX (OS Therapies)|RADX: Multiplikator P/S|Artiva Biotherapeutics Inc. - Rasio kapitalisasi pasar marang pendapatan|ANL (Adlai Nortye) - Multiplikator P/S|Multiplikator P/S verupharma.com|Kapitalisasi marang pendapatan TPST (tempesttx.com)|Kapitalisasi marang pendapatan Xilio Therapeutics Inc XLO|Multiplikator P/S RENB (Enochian BioSciences)|Mural Bio - Rasio rega marang pendapatan|KAPA - Rasio rega marang pendapatan|OnKure Therapeutics (OKUR) - Kapitalisasi marang pendapatan|GDTC: Multiplikator P/S|Rega marang dodolan Curis Corp (CRIS)|APLM (apollomicsinc.com) - Multiplikator P/S|Kapitalisasi marang pendapatan Tharimmune Corp (THAR)|Multiplikator P/S ADVB|GNPX - Rega marang dodolan|Rasio rega marang pendapatan calidibio.com CLDI|SBFM - Kapitalisasi marang pendapatan|XBIO - Rasio rega marang pendapatan|SLRX: Rasio rega marang pendapatan|Purple Biotech (PPBT) - Rasio rega marang pendapatan|AON - Rasio kapitalisasi pasar marang pendapatan|Kapitalisasi marang pendapatan BGNE|Multiplikator P/S Checkpoint Therapeutics Inc.|Multiplikator P/S ELEV|Kapitalisasi marang pendapatan iCAD ICAD|Multiplikator P/S IKNA (Ikena Oncology, Inc.)|Rasio kapitalisasi pasar marang pendapatan NTBL|Viracta Therapeutics, Inc. - Multiplikator P/S|Rasio kapitalisasi pasar marang pendapatan MOR (MorphoSys Inc)|NAYA (NAYA Biosciences Inc) - Kapitalisasi marang pendapatan|Kapitalisasi marang pendapatan Ascentage Pharma Group Ltd